Clearmind Medicine (CMND) has officially enrolled its first patient in a Phase I/IIa clinical trial for CMND-100, a new potential treatment for Alcohol Use Disorder (AUD). The trial, now underway at the Yale School of Medicine’s Department of Psychiatry, marks a significant milestone for the company as it tests the safety, tolerability, and early signs of effectiveness of this innovative, MEAI-based oral therapy.
CMND-100 is designed to target the root causes of AUD, with early evidence suggesting it could help reduce alcohol cravings and consumption. Clearmind is conducting the trial at multiple sites, including Johns Hopkins University, and is considering adding more locations as the study progresses. Participants include adults aged 18 to 60 who either seek treatment for AUD or report frequent binge drinking, and who express a desire to cut back or stop drinking.
Clearmind CEO Dr. Adi Zuloff-Shani emphasized that the treatment could address a major gap in the current approach to AUD, which remains a global health challenge. With the U.S. market for substance use disorder treatments alone valued at over $35 billion in 2021 and expected to reach more than $60 billion by 2029, the potential impact of CMND-100 is significant.
The company is building a robust intellectual property portfolio around its psychedelic-derived therapies, which currently includes 31 granted patents.
The post Clearmind Medicine Kicks Off Phase I/IIa Trial for CMND-100 in Alcohol Use Disorder appeared first on PRISM MarketView.